A significant percentage of cancer patients find out they are not eligible for their next round of chemotherapy when they arrive at the hospital, due to a low white blood cell count.
If the results of the hospital-administered test fall outside normal ranges, it leads to a delay in treatment and the patient being sent home. This is resource-inefficient, time consuming and burdensome for already vulnerable patients.
The inability to correctly and rapidly identify a respiratory tract infection can lead to outbreaks and ineffective treatments, resulting in an increase in suffering, time in hospital, spread of infection and antibiotic resistance.
Globally, there are millions of deaths each year related to respiratory tract infections, with COVID-19 as a prominent example. Lack of efficient and sufficient testing makes it difficult to curb outbreaks quickly.
As it stands, most testing either takes place in the laboratory, meaning delays in receiving results, or if portable testing is possible, requires expensive equipment, takes time and is inefficient. There is a growing call for tests which can analyze for multiple targets, including bacteria and viruses, simultaneously.
“miDiagnostics has the potential to disrupt and transform the industry by making diagnostic information available to clinician and patient alike.”
“Its easy-to-use and cost-efficient test will revolutionize point-of-care testing by directly engaging with patients and enabling speedy intervention”
“When it comes to making diagnostic decisions, it’s time to stop focusing on firefighting, it’s time to start investing in smoke detectors”